CClinicalTrials.gg
CompletedNCT03614637Updated Jul 7, 2020

Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells

An observational study in Cannabis Use, sponsored by Duke University. Completed at 1 site in United States. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-07.

Sponsored by Duke University · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
42
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

This is a follow-up project to a proof-of-concept study to determine if Cannabis use in male humans is associated with changes in deoxyribonucleic acid (DNA) methylation profile of sperm. This proposal will examine the epigenome of sperm from men actively using Cannabis before and after a period of Cannabis abstinence. The results will be compared to control non-users.

Read the detailed description

This project involves recruitment of 72 healthy males between the ages of 18 and 40 years. Forty eight of the participants will be regular cannabis users with a self-reported frequency of at least once weekly over the past 6 months, and a control group of twenty four cannabis non-users. Cannabis users will be asked to quit using cannabis for 11 weeks and will be required to attend 25 visits during the 11 week abstinence/contingency management period. Non-users will be asked to return to the clinic once a week for 11 weeks. Abstinence will be determined by self-report, qualitative urine rapid screening test at the clinic and quantitatively via Enzyme Immunoassay (EIA) analysis of THC (cannabinoids) and, by Liquid Chromatography Tandem Mass Spectrometry (LCMSMS) analysis of 11-nor-9-carboxy-∆ 9-tetrahydrocannabinol (THCCOOH) performed by an analytical lab contracted by the study team. Semen sample for both groups will be collected prior to the start of abstinence and after 11 weeks. Semen analysis and DNA methylation of sperm cells will be compared.

02

Conditions studied

  • Cannabis Use

Browse trials for

Keywords

  • Cannabis Abstinence Sperm Cells
03

In context

Marijuana Abuse

517 studies on the registry are indexed under Marijuana Abuse; 114 are open to participants now.

This study's enrollment of 42 is below the median of 100 across 78 observational studies indexed under Marijuana Abuse.

Browse Marijuana Abuse studies →

Lead sponsor

Duke University is the lead sponsor of 2,025 studies on the registry; 275 are open to participants now.

Of its 194 completed or terminated interventional studies of FDA-regulated products, 159 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

72 healthy males between the ages of 18 and 40 years. Forty eight - regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months, Twenty four Cannabis non-users - control group

Inclusion criteria

  • Male gender
  • Between the ages of 18-40 years, inclusive;
  • Free from significant medical/psychiatric conditions
  • Willingness to provide baseline semen sample and again at the end of study participation
  • Willingness to comply
  • Ability to communicate verbally and in written form in English.

For the CANNABIS USER group:

  • Self-reported Cannabis use of at least once weekly for past 6 months;
  • THC level of at least 50 ng/ml (EIA, non-creatinine adjusted value) and THCCOOH level of at least 15ng/ml (LCMSMS, non-creatinine adjusted value);
  • Positive result on urine rapid screening test for THC; and
  • Willingness to abstain from Cannabis for 11 weeks during the course of the study

For the CANNABIS NON-USER group:

  • Self-report of no Cannabis use in the past 6 months; fewer than 10 times lifetime;
  • THCCOOH level = 0 ng/ml; (EIA non-creatinine adjusted value) and
  • Negative result on urine rapid screening test.

Exclusion criteria

Exclusion Criteria:

  • Positive result for any other drugs of abuse on urine rapid screening test (including cocaine, methamphetamine, opiates, benzodiazepines, and barbiturates); or use of nicotine or tobacco products;-Currently prescribed any psychoactive medication;
  • Current diagnosis of any significant psychiatric condition, including substance use disorders. For the user group, Cannabis Use Disorder that does not require immediate clinical attention in the opinion of the clinician/investigator will be allowed.
  • Score on the Marijuana Screening Inventory-X > 10;
  • Score on the Alcohol Use Disorders Identification Test > 8;
  • Expired breath CO reading of > 8 ppm at screening and throughout the study.
  • Expired Breath Alcohol Level of > 0.000 at screening.
  • Urinary cotinine level greater than 2- indicating urinary concentrations of > 30ng/ml cotinine at screening and throughout the study
  • Estimated IQ \< 80 as assessed by the Kaufman Brief Intelligence Test, Second Edition; and
  • Unable to comply with study requirements or otherwise unsuitable for participation in the opinion of the study physician and/or study psychologist.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
42 participants (actual)
Patient registry
No

Groups and cohorts

  • Cannabis User Group

    Forty eight participants who are regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months of screening visit.

    Other: Cannabis use abstinence for 11 weeks

  • Non-Cannabis User Group

    Twenty four participants who self-report no Cannabis use in the past 6 months of screening visit and fewer than 10 times during their lifetime

Interventions

  • OtherCannabis use abstinence for 11 weeks

    Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.

06

What researchers measure

Primary outcomes

  1. Group differences in sperm DNA methylation profiles between user and non-user group

    We will compare the overall DNA methylation profiles in sperm cells of user and non-user group to replicate findings in the pilot study.

    Time frame: Baseline

  2. Within group change in DNA methylation profiles from baseline to after 11 weeks of Cannabis abstinence

    We will compare the overall DNA methylation profiles in sperm cells after an 11 week period of Cannabis abstinence in the user group

    Time frame: Baseline to after 11 weeks of abstinence from Cannabis use.

Secondary outcomes

  1. Group differences in the sperm analysis profile between user and non-user group

    We will compare the overall sperm analysis profile of user versus non-user group to replicate findings in the pilot study

    Time frame: Baseline

  2. Within group change in sperm analysis profile from baseline to after eleven weeks of Cannabis abstinence

    We will compare sperm analysis profile after an eleven week period of Cannabis abstinence in the user group

    Time frame: Baseline to after 11 weeks of abstinence from Cannabis use

07

Study locations

1 site
  • Duke Child and Family Study Center
    Durham, North Carolina 27705, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03614637
Lead sponsor
Duke University
Collaborators
John Templeton Foundation
Responsible party
Sponsor
First posted
Aug 3, 2018
Start date
Nov 7, 2017
Primary completion
Mar 16, 2020
Completion
Mar 16, 2020
Last update
Jul 7, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion